Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

acTBS Treatment for Inpatient Subjects With Suicidality

NCT: NCT04197765 · ACTIVE_NOT_RECRUITING

NCT IDNCT04197765
StatusACTIVE_NOT_RECRUITING
Start Date2020-01-01
Completion2029-01-01

Brief Summary

This is a pilot study to analyze the benefit of accelerated continuous Transcranial magnetic stimulation for inpatient subjects suffering with suicidal ideation. This study will enroll 40 inpatient subjects recruited from the Resnick Neuropsychiatric hospital. Subjects will be blinded and randomized to active or sham TMS treatment and will receive up to 5 assigned treatments per day. Subjects will also be asked to complete mood surveys throughout their participation. Participation in this study will last 7-10 days depending on scheduling.

Frequently Asked Questions

What is acTBS Treatment for Inpatient Subjects With Suicidality?

acTBS Treatment for Inpatient Subjects With Suicidality is a clinical trial registered under NCT04197765. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04197765?

The current status of NCT04197765 (acTBS Treatment for Inpatient Subjects With Suicidality) is: ACTIVE_NOT_RECRUITING.

When did acTBS Treatment for Inpatient Subjects With Suicidality start?

acTBS Treatment for Inpatient Subjects With Suicidality started on 2020-01-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.